ArticleIranian journal of basic medical sciences2025
Down-regulation of neuregulin2 (NRG2) following spinal cord injury in C57BL/6 mice: Its implications in therapeutic potential.
Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to elucidate the alterations in neuregulin 2 (NRG2) and its receptor ErbB4 following spinal cord injury (SCI), as well as to investigate the neuroprotective mechanisms of NRG2 in neurons. Materials and Methods: Dataset GSE93561 was analyzed to verify the changes of NRG2-ErbB4 signaling pathway in mice following SCI. The levels of Iba-1 and NRG2 were analyzed by immunohistochemistry, and NRG2 and pErbB4 protein levels were detected by western blot. HT22 cells were scratched and treated with NRG2 dosed from 0-5 nM. Cell mobility was measured at the time point of 0, 24, and 48 hr after scratch. Additionally, western blot was used to detect the protein levels of pErbB4 and pAkt1 at 48 hr. Results: By analyzing dataset GSE93561, NRG1, NRG2, and NRG3 were found to be decreased to different degrees post-SCI in mice. The results of immunohistochemistry showed that the level of Iba-1 in the injured core area was significantly increased 8 weeks post-SCI. Western blot analysis showed that the protein levels of NRG2 and pErbB4 were decreased significantly post-SCI. NRG2 promoted HT22 cell migration and dose-dependently increased pErbB4 and pAkt1 protein levels at doses ranging from 0-5 nM. Conclusion: The NRG2-ErbB4 signaling pathway was inhibited after SCI in mice. NRG2 promotes the healing of HT22 cells after scratch injury, and the mechanism of NRG2 in the treatment of SCI may be ascribed to the activation of PI3K-Akt signaling pathways downstream to NRG2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.